

**Selective flexible packaging pathways of the segmented genome of Influenza A  
Virus**

Haralampiev et al.

**Supplementary Information**

## 1 **Supplementary Method**

### 2 ***Calculation of all possible combinations of vRNPs***

3 Considering all possible combinations of vRNPs, the random packaging model predicts  
4 that 98% of the MSCs would contain two or more copies of a distinct segment species.

5 This value follows from the equation:

$$6 (1 - (\text{Combinations without repetitions} / \text{Combinations with repetitions})) * 100\% \quad (1)$$

7 with

8 Combinations with repetition (up to k copies of a segment can occur in an MSC of rank  
9 k; n – number of different segments (n = 8))

$$10 \frac{(n+k-1)!}{(n-1)!k!} = \binom{n+k-1}{k} = \binom{n+k-1}{n-1} = \binom{n}{k} \quad (2)$$

11 and

12 Combinations without repetition (only one copy per segment occur in an MSC of rank  
13 k; n – number of different segments (n = 8))

$$14 \frac{n!}{(n-k)!k!} = \frac{n(n-1)(n-2)\dots(n-k+1)}{k!} = \binom{n}{n-k} = \binom{n}{k} \quad (3)$$

15

## 16 **Supplementary Note 1**

### 17 ***Imaging of vmRNA***

18 To verify specificity of vRNA probes, we visualized all major vmRNAs (Fig. 1, vmRNA)  
19 except for M2 and NS2 (see Mat. and Meth.). Cytosolic vmRNA spots did not  
20 significantly colocalize with each other or with vRNAs. It is important to note that probes  
21 targeting vmRNA also recognize viral cRNA due to the high similarity of their  
22 sequences. vmRNA copy numbers have been reported to be about 100-fold higher  
23 than cRNA transcripts, which are almost exclusively localized to the nucleus<sup>1, 2</sup>, so the  
24 contribution of the latter RNA species to fluorescent spots was ignored. Our analysis  
25 of the intracellular localization of vmRNA species revealed differences in their  
26 distribution between the nucleus and cytosol (see Fig. 1). vmRNAs of PB2, PB1, PA  
27 and NA appeared to predominantly localize to the nucleus (Supplementary Figure 6),  
28 while the remaining vmRNAs were either rather equally distributed between the  
29 nucleus and cytoplasm (HA, NP, M1) or were largely found in the cytoplasm (NS1).  
30 While here we visualized vmRNAs for the sole purpose of demonstrating the specificity  
31 of our FISH probes, we observed a different distribution of vmRNAs between the

32 nucleus and cytoplasm than found in a previous study on A/PR/8/34-infected 293T  
33 cells<sup>3</sup>. Namely, the vRNAs of PB2, HA, NP, M1 and NS1 were found predominantly  
34 localized in the cytosol. Further studies are needed to clarify the extent to which  
35 vRNA distributions are dependent on the strain of IAV and/or target cell line used in  
36 a study.

37

## 38 **Supplementary Note 2**

### 39 ***Verification of vRNA spot binning***

40 For an assessment of the colocalization quality, we calculated the center of mass  
41 for each MSC according to (here shown for x coordinate):

$$42 \text{(Center of Mass)}_x = 1/N \sum_k x_k \quad (4)$$

43 The index  $k$  runs over all segments in the MSC.  $N$  is the number of segments in the  
44 MSC. The center of mass for y coordinates were calculated accordingly. Next, the  
45 distance of each spot towards the center could be calculated and plotted in a  
46 histogram (Supplementary Figure 12). Most segments showed a distribution with  
47 a marked peak relatively close to the center of mass (25-60 nm distance), with a  
48 shoulder towards higher distances up to 250 nm. All in all, even though one or more  
49 segments frequently showed signs of sub-optimal registration, distances were still  
50 within the cylinder volume that allowed colocalization to be detected.

51

## 52 **Supplementary Discussion**

### 53 ***Potential role of specific vRNPs in MSC assembly***

54 Although we observed this situation only for a few cells, very likely due to the high MOI  
55 used in our experiment, of particular interest for understanding the potential role of  
56 segments in MSC assembly are those cells in which one vRNP species is of low  
57 abundance in comparison to the other vRNPs. In principal, two situations are  
58 interesting. First, if any segment is 'less important' in the packaging of MSCs, and only  
59 becomes relevant in a late step of packaging, such as in the formation of rank 8 MSCs,  
60 we would anticipate a u-shaped MSC frequency distribution with a high occupancy of  
61 rank 7 complexes and a rather low occupancy of rank 8, due to the short supply of that  
62 specific segment. We observed such a u-shaped frequency distribution of MSC ranks  
63 for cells with a low fraction of segment 8 (Fig. 3d and h, 'Cell 29'). This suggests that  
64 at least for A/Panama, this segment is dispensable in the segment packaging pathway

65 and only relevant for the final step of formation of a complete set of segments, that is  
66 MSCs of rank 8.


67 A second interesting situation concerns the case where a segment which plays an  
68 important role already in early steps of MSC assembly is of low abundance. In that  
69 case we should expect a left-hand distribution with a frequency maximum for low rank  
70 MSCs and a decreasing frequency towards high rank MSCs. We observed such cells  
71 even more rarely. In addition, these cells exhibited the low abundance of at least two  
72 segments, which does not permit a distinction regarding whether both or only one of  
73 the segments are important for early steps of MSC assembly. An exception is 'Cell 23'  
74 (Fig. 3c,g,k), which exhibited low quantities of both S1 and S8 (Fig. 3g). As S8 seems  
75 to play a decisive role only in the formation of MSCs (see above), the left-hand side  
76 MSC frequency distribution found for 'Cell 23' (Fig. 3c) points towards an important  
77 role of the long vRNP segment S1 in the early and/or intermediate phase of MSC  
78 formation. Of course, this conclusion must be taken with great caution as this is the  
79 only cell we could evaluate. Nevertheless, these examples illustrate that frequency  
80 distribution analysis is a very useful tool to uncover the role of vRNPs in MSC  
81 assembly.

82 **Supplementary References**

- 83 1. Kawakami E, *et al.* Strand-specific real-time RT-PCR for distinguishing  
84 influenza vRNA, cRNA, and mRNA. *J Virol Methods* **173**, 1-6 (2011).
- 85 2. Shapiro GI, Gurney T, Jr., Krug RM. Influenza virus gene expression: control  
86 mechanisms at early and late times of infection and nuclear-cytoplasmic  
87 transport of virus-specific RNAs. *J Virol* **61**, 764-773 (1987).
- 88 3. Read EK, Digard P. Individual influenza A virus mRNAs show differential  
89 dependence on cellular NXF1/TAP for their nuclear export. *J Gen Virol* **91**,  
90 1290-1301 (2010).

91

92




94

95 **Supplementary Figure 1: Localization of vRNA and vmRNA in A/Panama-infected**  
 96 **A549 cells identified by MuSeq-FISH.** (a, b) Viral genomic RNAs were stained by  
 97 FISH 10 h p.i. (MOI 5). To cover all vRNAs and major vmRNAs 12 cycles of FISH  
 98 labelling were performed. Along these cycles each vRNA was targeted twice, once with  
 99 with Atto550 (a) (see also Fig. 1) and once with STAR635P (635P) (b) labelled probe  
 100 sets (for details see text). (c) Immunofluorescence staining of NP. DAPI labelling was  
 101 performed to exclude nuclear vRNA spots for further colocalization analysis. (d) All  
 102 major unspliced vmRNAs were stained. Images represent max-z-projections. The  
 103 intensities of images were scaled according to corresponding images taken after probe  
 104 removal by formamide. Scale bars correspond to 10  $\mu$ m. Representative images of  
 105 four independent experiments are shown.

106



107



108

109 **Supplementary Figure 2: Comparison of FISH probe removal by formamide and**  
 110 **by DNase I probe digestion.** A549 cells were infected with A/Panama for 10 h, fixated  
 111 and stained by FISH targeting mRNAs of PB2 (Atto550-coupled probes) and PA  
 112 (STAR635P-coupled probes). DNA-Probes were removed either by washing with 80 %  
 113 formamide for 10 min at 37 °C (a) or by cleavage with DNase I for 3 h at 37 °C (b).  
 114 FISH 1 corresponds to the first staining cycle. After treatment with formamide, the  
 115 signal intensity of the following labelling cycle (FISH 2) was significantly increased  
 116 using the same probe sets and fluorophores as in the first FISH cycle. This was not  
 117 observed for probe removal by DNase I. Here, we found partially decreased signal  
 118 intensity for FISH 2 in comparison to FISH 1. Note, for improved visual distinction FISH  
 119 1 and FISH 2 are shown in different colours (magenta, green) although the same  
 120 fluorescent probe sets were used. Scale bars 10 µm. Experiment was performed once  
 121 as proof of principle.






122


123 **Supplementary Figure 3: Mean fluorescence intensity of PB1 vRNA in six runs**  
 124 **of MuSeq-FISH.** A549 cells were infected with A/Panama and fixated 10 h p.i. (a) FISH  
 125 was performed to visualize PB1 vRNA using Atto550 probes in six sequential cycles.  
 126 After each staining probes were removed by formamide washes. (b) A ROI was defined  
 127 to measure the mean fluorescence intensity before and after removal of probes by  
 128 ImageJ. The data documents successful PB1 vRNA staining and probe removal in  
 129 each cycle. Moreover, formamide treatment enhanced FISH signal intensity of  
 130 subsequent FISH staining - with the strongest increase after the first cycle. Specific  
 131 FISH signal was significantly higher than the signal remaining after washing with  
 132 formamide. For images, fluorescence intensity was scaled equally for all cycles  
 133 according to that of images after formamide washing. Mean and s.e.m. of all pixels  
 134 within the ROI are shown. Experiment was performed once as proof of principle. Scale  
 135 bars correspond to 10  $\mu$ m. Source data are provided as a Source Data file.






138 **Supplementary Figure 4: Influence of formamide (FA) treatment on**  
 139 **immunofluorescence (IF).** A549 cells were infected with A/Panama and fixated 10 h  
 140 p.i. IF for influenza NP was either conducted before (a: IF→ FA) or after (b: FA→ IF)  
 141 washing with 80% formamide. As a respective intensity scaling control, antibody  
 142 staining was conducted without formamide treatment. Irrespective of the particular  
 143 order, in general, any formamide wash decreased IF signal intensity significantly. But  
 144 the overall signal was still significantly higher when immunofluorescence was carried  
 145 out first (upper row) rather than after a formamide wash (lower row). For this reason,  
 146 immunofluorescence labelling is strongly recommended to be performed before the  
 147 MuSeq-FISH cycles. Scale bar corresponds to 10 µm. Images are from one experiment  
 148 as proof of principle.

149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169



**Supplementary Figure 5: Detection of vRNA in IVB/Lee infected A549 cells.** Cells were stained by a mixture of all Atto550-coupled viral genomic RNA probe sets of A/Panama 10 h p.i. (MOI 5). Using the same conditions of image acquisition as for A/Panama, no signal of vRNA probes could be detected (see 'all vRNA'). NP was stained by immunofluorescence using first an unlabelled primary mouse antibody (MCA403, Bio-Rad, Hercules, Germany) targeting IVB NP and second an Alexa Fluor 488-labelled goat anti mouse antibody (ab150117, Abcam, Cambridge, UK) . DAPI was used as counterstaining for nuclei. Scale bar corresponds to 10  $\mu$ m. Images are from one experiment.

170



171

172


173 **Supplementary Figure 6: High nuclear density of polymerase and NA mRNA**

174 **species.** Images correspond to mRNA data of Fig. 1. Signal intensity contrast was

175 increased to demonstrate the occurrence of spot-like vmRNA signals in the cytosol.


176 Scale bar corresponds to 10  $\mu$ m.

177




178

179 **Supplementary Figure 7: Frequency distribution of the number of vRNP**  
 180 **segments per cell for all eight vRNP segments.** Data are taken from 69 cells (see  
 181 Fig. 2). Distributions were fitted by a Gaussian function (straight line) using PRISM  
 182 (version 6.0d, GRAPHPAD Software, Inc.). All fits passed normality test by D'Agostino-  
 183 Pearson with  $p=0.05$  (one-sided).  $R_2$  is the correlation coefficient. Source data are  
 184 provided as a Source Data file (see page Segment Distribution (data of Fig. 2)).



187 **Supplementary Figure 8: qRT-PCR measurements of vRNAs and vmRNAs in**  
 188 **A/Panama-infected A549 cells.** A549 cells were infected with A/Panama at MOI of 5  
 189 for 2, 4, 6, 8, 10, and 12 h. Afterwards, RNA was extracted with an RNeasy extraction  
 190 Kit (Qiagen, Hilden, Germany). The extracted mRNA was specifically transcribed with  
 191 an anchored poly-dT-primer (Life Technologies, Henningsdorf, Germany) and the  
 192 vRNA with an UNI12-primer (AGCAAAGCAGG) recognizing the highly conserved  
 193 5'end of the viral segments into DNA by SuperScript IV polymerase (Life Technologies,  
 194 Henningsdorf, Germany). Subsequently, remaining RNA molecules were cleaved by  
 195 RNase H (Life Technologies, Henningsdorf, Germany) and qRT-PCR measurements  
 196 were performed with SYBRgreen (KAPA Biosystems, Wilmington, MA, USA) and  
 197 segment-specific primers. Three biological and three technical replicates were  
 198 measured. The results show a strong increase over time for vmRNAs except for PB2  
 199 and PA mRNAs. This increase of vmRNAs is stronger compared to the raise of vRNAs.  
 200 At 10 h p.i. the maximum values for HA, NP, NA, M1 and NS1 mRNAs were reached.  
 201 Note, mRNA for M2 and NS2 were not measured (see Material and Methods).  
 202 Genomic vRNAs increased continuously without reaching a plateau phase within the  
 203 time frame of the experiments. Time dependence of expression levels were similar for  
 204 all vRNAs. Mean and s.e.m. of  $n = 3$  independent experiments are shown. Source data  
 205 are provided as a Source Data file.




207

208

209 **Supplementary Figure 9: Frequency distribution of MSC ranks after 6 h p.i. (MOI**  
 210 **5).** A total of  $2.6 \times 10^5$  distinct segment spots were detected in  $n = 84$  A/Panama-infected  
 211 A549 cells of three independent experiments and binned into  $2.1 \times 10^4$  MSCs. Mean  $\pm$   
 212 s.e.m. are shown. Source data are provided as a Source Data file.

213

214




216

217 **Supplementary Figure 10: Localization of vRNA and vmRNA in A/Mallard-**  
 218 **infected A549 cells identified by MuSeq-FISH.** Viral genomic RNAs were stained by  
 219 FISH 10 h p.i. (MOI 5). To cover all vRNAs and major vmRNAs, 12 cycles of FISH  
 220 labelling were performed. Along these cycles each vRNA was targeted twice, once with  
 221 Atto550 (shown here) and once with STAR635P (Supplementary Figure 1) labelled  
 222 probe sets (for details see text). High degree of colocalization was observed for all  
 223 vRNA segments (white colouring in vRNA overlay). IAV NP stained by  
 224 immunofluorescence displayed the same spot pattern as the vRNA spots. DAPI  
 225 labelling was performed to exclude nuclear vRNA spots for further colocalization  
 226 analysis. All major unspliced vmRNAs were stained. Images represent max-z-  
 227 projections. The intensities of images were scaled according to corresponding images  
 228 taken after probe removal by formamide. Scale bars correspond to 10  $\mu$ m.  
 229 Representative images of  $n = 3$  independent experiments are shown.




230



231

232 **Supplementary Figure 11: Colocalization of the different A/Panama vmRNA**  
233 **species of a representative microscopy position.** All vmRNAs were analysed with  
234 the same settings for identification of colocalization that were applied to vRNA. Source  
235 data are provided as a Source Data file. A representative position from data of Fig. 1  
236 was used to analyze vmRNA colocalization.


237



238


239

240 **Supplementary Figure 12: Distance of vRNP spots to Center of Mass in MSCs.**  
 241 vRNA spots colocalising within a cylinder of radius 300 nm and height 1000 nm were  
 242 binned into one MSC. For MSCs, the Center of Mass (centroid) in x and y directions  
 243 were calculated. Then, distributions of distances of spots to centroids were  
 244 calculated for each segment. High distances indicate sub-optimal image  
 245 registration and a bias towards a shift of spots of this segment in comparison to  
 246 the other segments. Here, segment 5 (NP) showed the least optimal registration  
 247 as its distribution was shifted towards higher distances. However, all spots and  
 248 their peaks are well localized within the colocalization radius of 300 nm.



250

251 **Supplementary Figure 13: STED vs. confocal microscopy.** A549 cells were fixated  
 252 at 10 h p.i. and FISH staining was performed with three colours: NS vRNA (red,  
 253 STAR635P), PA vRNA (green, Atto594), PB2 vRNA (blue, Atto655). Images were  
 254 taken in confocal as well as in STED mode. Lateral resolutions were calculated to be  
 255 310 nm (confocal) and 79 nm (STED), respectively. Images show high degree of  
 256 colocalization for all three colours. Most of confocal single spots were also classified  
 257 as single spots by STED (Region 1). In a few cases multiple spots identified by STED  
 258 appear as a single spot in the confocal image (Region 2). Scale bars correspond to 1  
 259  $\mu\text{m}$ . Representative images of  $n = 3$  independent experiments are shown (for details,  
 260 see Methods).



261

262 **Supplementary Figure 14: Predicted vs measured abundances for individual**  
 263 **MSC ranks 2 to 7.** Prediction is based on the mathematical model described in the  
 264 Method Mat. and Meth. section. The plot shows predicted vs. measured abundance of  
 265 an MSC of specific rank and specific composition. The Pearson correlation coefficient  
 266 (R) is shown for each plot. For an exemplary illustration see Supplementary Table 2.  
 267 Source data are provided as a Source Data file.

**Supplementary Table 1**

<p><b>A/Panama PB2 vRNA</b> AACGGGACTCTAGCATACTT TGTGCTAATTGGGCAAGGAG CAGAAGATACGGACCAGCAT AAAGCACATCCGGAGTGGAG CACTTTAATTGAAGACCCAG CAATTCTCGGAAAAGATGCC TCAACTACAACAAGACCACT CTTGGGACATTTGATACCAC TCTCAGAATCCTGCAATGTT GATTAACGGTCTGAGTCGG ACACAGGGAACAGAGAGACT TGGTTAGCATTGATCGGTTT GTCAGCAAAATGGGTGTGGA GACAGTGTGATGGGAATGGT TGCATCAGCTTTTAAAGGCAT TTTTCGTCAACAGGGCAAACC GTTTTTACAAGAGGATTGCA AGCCGAAGCAATAATCGTGG AGATTGGTTCAGCTCATAGT CCGACTGAAGAACAAGCTGT GGTGGACATTCTTAGGCAGA ATCAGCAGATCCACTAGCAT GAGGAATGACGATGTTGACC GACTCAAGGAACGTGTTGGG GGCGGAACAAGCAGTATATA TAGAGAGAGAATTGTCCGA GTCAAGATACGCCGAAGAGT ATGGACCTGTGACAAGTACG GCTGTGACATGTTGGAATAG CAGAAATGGTTCGGGAGAGA</p>	<p><b>A/Panama PB1 vRNA</b> CGAGTCTGGACGGATTAAGA CGGATTGATGCCAGAATTGA GGAGACCGGTTGGAATTTCT GTGCTGCAACTTTGTCGAGA GCCATAAAGAGATTGAGTCT TGGATGAGGATTATCGGGGA ACATTCGCCGAAGTCTGCTTA CCCAATCAAAGGCAGGACTA CTAAAGAAGCTGTGGGATCA TCAGACGAGAAGATCATTCC AATGACCTTGGACCAGCAAC CAGTTTTGGAGTGTCTGGAA GGATAGATTCTACAGGACCT TTTTGCCCTCATAGTGAATG AGTACGGTTTTAGGAGTCTC GCATCGACCTGAAGTATTT GAGAATGAAGCTCCGAACAC AAGGATACATGTTCCGAGAGT GCATCGCACCAATAATGTTT GGTTCGTGTACTTCTGTTGAA AACACCCGGGATGCAATTA CCAAAGATGCAGAGAGAGGT GCTAATGAATCGGGAAGGCT GAAATCAACCCGGCAGCACT GCCGACTTATGATTGGACA AGGGTGGACAACTAACTCA ACCTGAGGATAATGAGCCAA AATACAGAACTGGGGCACC CAGAAAAGGGGAAGTGGACG TTTTCTAAAGGTTCCAGCG</p>	<p><b>A/Panama PA vRNA</b> CAATGCGTCTTGGTTCAACT CTTTGATCTTGGGGGGCTAT TCTTAGGGACAACCTCGAAC AAGGATTTTCAGCGGAGTCA GGCTAAGTCCGTGTTCATA CCAAGGGAGTGGAAGAAGGT ATAAATCAGAAGCATGGCCC TTGTATGTGAGGACAAACGG CCAAATTTCAAGGCCTATGT TACTGTGTCCTTGAGATAGG AGAGGGGAAGGCGAAAAACCA CATTAACTACTGCCTTGCTCA GACATAAGCGATTTGAAGCA AGTAGACTTTGACAACTGCA TCAGAGTTGCAGGACATTGA ATTACCTGCTGTCATGGAAG CAAACCACACGAAAAGGGGA CAAATTCCTCTGATGATG GAATGGACCTCCTTGTATC AGGAACTATGCGCAGGCTTG TCAGTCCGAAAGAGGCGAAG CCAGGCTATTTACCATAAGA GGAAAGCAGGGCTAGGATTA CCACAAAGGCAGACTACACT GTGACAAGGAGAGAAGTCCA CCGAAGTTTCTACCAGATTT CAACACTACTGGAGCTGAGA GGCATGGACAGTAGTAAACA TAGAGGGGAGAGACAGAACA CAAGGCGAATCAATAGTGGT</p>	<p><b>A/Panama HA vRNA</b> TTGCTGGGGTTCATCATGTG CGAAGCATTAAACAACCGGT CTGCATAGGGTCAATCAGAA TGCTGAGGATATGGGCAATG AGATCTCTGGTCGTACAACG CCAAATCAACGGGAAACTGA AAAGCACTCAAGCAGCAATC CACAGGACAAGCAGCAGATC GTACGGTTTCAGGCATCAAAA TTGGGAGGGAATGGTGGACG TCGCGGGTTTCATAGAAAAAT ACCTAGAGGCATATTCGGCG GATGCGGAATGTACCAGAGA ACACTCTGAAATGGCAACA TGTCCAGATATGTTAAGCA AGATGCACCCATTGGCAAAT CTCCTCGGGGTTACTTCAA GTAAAACCGGGAGACATACT CTCCAGCAGAATAAGCATCT CCAACAACTGTAATCCCGA GAGTACGGACAGTGACCAAA CTGAACGTGACTATGCCGAA TCGCTCAGAATGGAACAAGC GAAAGCTTCAATTTGGACTGG CGGCACACTGGAGTTTAAACA CTTATGATGTGCCGATTAT GGAATGGGACCTTTTTGTTG GAATATGCGACAGTCTCAC GTTTCAGAGTTCTCAACAGG TTTCGCTCAAAAACCTCCCG</p>
<p><b>A/Panama NP vRNA</b> GAAGGCAACGAACCCGATCG GAGTTTTTCGACTCTCAGAC TCACTGGAAATACGGAGGGA CCAAATCAGTGTGCAACCTA TACTAATCAACAGAGGGCCT ACTGAGAAGCGGTTACTGGG ATATGGGATCAAGTACTCTT GCGGGGAAACTTTCAACTA GTTAAGCTTCATCAGAGGGA TCAGACCCGACGAGAATCCA AATAGCCAAGTATACAGCCT TGTGTATGGACTCGAGTAT CACAAATCTTGCTACCTGC TGAGAGAAAGTCCGAACCCA GCACAAGAGCAATGGTGGG GGGCGGAAAACAAGAAGTGC CGAAATTTCTGGAGAGGTGA TCAGAATGGTCAAACGGGGG GAATGTGCTCTCTGATGCAG CGACAGCTGGTTTAACTCAC CCCATATACAGGAGAGTAGA GATATCTGGAAGAACACCCC AGAAAATGGTCTCTCTGCT TGATCCAAAACAGCTTGACA CTCAGTGATTATGAAGGGCG CCAAATGTGCACTGAACCTA GCCAGAATGCAACTGAGATT AGGCACCAAACGGTCTTATG ACATCAAAATCATGGCGTCC GCAGGGTTAATAACTACTCA</p>	<p><b>A/Panama NA vRNA</b> ATTGTTGTGTTTTGTGGCAC AAGTCTGGTGGACCTCAAAC GTGCTTTTATGTGGAGTTGA GAAAGAGGTAATATGTCCGG GCAGATAAATAGGCAAGTCA GGTCCAAACCTAACTCCAAA AGAAGTCACGCTCAGGTTAT CGTGTGGATGGGAAGAACGA TGGGCCTTTGATGATGGA AGGGGGTTCATGGAGTGA GCCTGGATCCTAACATGAA TATGTGTGCTCAGGACTGT GGATTATAGCATTGTTTCCA CTCCTGTTATCCTCGATATC CGTTCATACTAGCAAATTTG ACTTTTCATTGAGGAGGGGA TCGGAATGCGTTTGTATCAA ATAGTATTGTTTATGTTCC ATTTACGATGGGAGACTTGT TGAAAATGCAACTGCTAGCT CACGATGGAAAAGCATGGCT TAGCATGGTCCAGCTCAAGT CTTATCGAACCCTATTGATG TGGACAGGGAACAACACTAA ACAAGTGTTATCAATTTGCC AACCTTATGTGTCATGCGAT AGGATTTGCACCTTTTTCTA ACAACCAAGTAATGCTGTGT CTACTGTAACATTGCATTTT CTTATGCAAAATAGCCATCCT</p>	<p><b>A/Panama M vRNA</b> GAGTACCTGAGTCTATGAGG GAAAAGAGGGCCTTCTACGG ATCGACTCTTCAAACACGGC CTTGCACTTGATATTGTGGA TGTTGCTGCGAGTATCATTG TGCAACGATTCAAGTGACCC CAGAAACGAATGGGGTGC TCCAGTACTGGTCTAAGAGA AACCCTTGGGACTCATCCTA AGGCAAATGGTGCAGGCAAT CATGGAGATTGCTAGTCAGG CACTACAGCTAAGGCTATGG GTCTCATAGGCAAATGGTGG CTGGTATGTGCAACATGTGA TAACCACCGAAGTGGCATT GGGCCTCATATACAATAGGA ATTTTGGGGTTTGTGTTTCA CTTGAGGCTCTCATGGAATG AAAGCCGAAATCGCGCAGAG CGTATGTTCTCTATCGTT AAGATGAGCCTTCTAACC</p>	<p><b>A/Panama NS vRNA</b> TTTATGCAAGCATTACAGCT AATGGCGAGAACAGCTAGGT TCCACTTACTCCAAAACAGA TCTACAGAGATTGCTTGGGA ACAGACTTCGAGTGTCTAAA CGGAGGGCTTGAATGGAATG AAAATGCAATTTGGGGTCTC GGACATACTATTGAGGATGT AGGGAGCAGTGTGGCGGAA TTACTAAGGGCTTTTACC TGGCCGACTAGAGACCATAG GCGAATTTTCAAGTGTGATCT TCAGAATGGACCAGGCAATC AACTGGTTCATGCTAATGCC CTGCTTCGGATACATAACT TAAAATGACCATGGCTCCA AACACTCTCGGTCTAGACAT CGAGATCAGAGGTCCCTAAG AACTGAGTGTGCCCCATT TCCGGAAGCAAGTTGTAGAC GGATTCCAACACTGTGTCAA AGCAGGGTGACAAGACATA</p>

**A/Panama PB2 mRNA**

ATTTCTCTCCGGAACCATTT  
 CTCCATAGAGTTTGTCTTG  
 TGGACCGTACTTGTACAGG  
 ATGAACAGGGCCAAAGGTTT  
 GGCGTATCTTGACTTGATTT  
 TGTATGCAACCATCAAGGGA  
 TCGGACAAGTTCTCTCTA  
 GCAACTGGGAGAAATCTTGT  
 TCAACATCGTCATTCCTCAC  
 GGCTGCAATAATTAGGCTTT  
 CGGCTCTTCTACTATGTTT  
 ACAGCTTGTCTTCAGTCGG  
 CTCTCTTTGACTGATGACC  
 TGTTTGAGATTGCCTGTAA  
 ACCATTGTGAACTCCTCATA  
 TATGAGCTGAACCAATCTCC  
 TATTGACTGTTCTGTCCTTC  
 GTCACCTCTAACTGCTTTTA  
 CACTTTGCGCATCTTTCTGAA  
 GTCATATCTGGTAATACTCC  
 CATTGACATCTCTGTGCTTG  
 CGATCAATGCTAACCACCAC  
 GTTAATCTCCACATCATTG  
 TGACCAAAACCGACTCAGGA  
 GGATTCTGAGACCATTGGAT  
 AGTGGTCTTGTGTAGTTGA  
 AATCCTCTCAAGACAGCGGA  
 AGGTTACTCAGTTCATTGAT  
 TTGCCAATTAGCACATTAG  
 TTCGTTCTATTACCAACACC

**A/Panama NP mRNA**

TCAGTTTCCATCTGTTTATA  
 CCTAATCTCAGTTGCATTCT  
 CATCAATCATCTTCCCGACG  
 TGGATGTAGAATCGCCCAAT  
 CTGAGTTAAAGTTCAGTGCA  
 AAGCTGTTTTGGATCAACCG  
 TGGGGTGTCTTCCAGATAT  
 ATCTACTCTCCTGTATATGG  
 TAAAGGACGAGTCCCTCAT  
 TGAGTTAAACAGCTGTGCG  
 CGGTTTCAACAAGAGCTCTT  
 CCTCTCCAGAAATTCGATC  
 TAAGCACTTCTGTTTTCCG  
 CGACTTTCTCTCACTTGATC  
 GATCTTCGATCTCAGCATTT  
 TATTAATGCAGATCTTGCCA  
 AGATTGTGAGCAACTGACC  
 CATAACACAGGCAGGTAGG  
 TTCGGTCTGATTAGGCTGTA  
 TCCCTCTGATGAAGCTTAAC  
 CGCTTCTCAGTTCAAGAGTA  
 AACGTAGGTTGCACACTGAT  
 CCATGACAGTTGACTTTTCA  
 CTCCGATTTCCAGTGAATG  
 TCTCGTCTGAGAGCTCGAAA  
 AAAAGAGGGCAGCATCGGGT  
 AATTGTGCTACTCTTCTGCA

**A/Panama PB1 mRNA**

TGTGTTCTGTTGACTGTGTC  
 CAGTTTCTGTATTTGTGCTC  
 TGGGATCTTCAAGGAAGGC  
 GGCAATGAGCTCTCAAAGATC  
 TGTTTGTGAACGACTTCCA  
 CTTGAGTTAGTTTGTCCACC  
 GTCCAATCATAAGTCTGGCG  
 TGCCGGTTGATTTCTGTTTA  
 TAATTTGCATCCCGGGTGT  
 TCAACGAAGTACACGAACCC  
 TTTGGCCTTCTTTTCAATTAC  
 TCTTTCTCACAACATTTGCC  
 GCTCTGTGCTTGTGAATTA  
 TCCCCAGTGATTGTGAAAGA  
 TCATCGCCAAGAACATTCGA  
 ATTATTGGTGCGATGCTCAG  
 TCGAACATGTATCCTTTTTCC  
 TTCGGAGCTTCTTCTCTTA  
 TAGCATTTCTGCGGGTATTT  
 AATACTTCAGGTGCGATGCTT  
 GAGACTCCTAAAACCGTACT  
 GACTTCTTTTTGCTCATGTT  
 CCACAAATCCATAGCGATAA  
 TCAATTTATCCAGACTCCTC  
 GGTCCAAGGTCATTGTTTAT  
 TCTGATACCAATAGTCTGCTC  
 GTTGATAAGTTTGGTCTCTC  
 GCAGACTTCGGGAATGTGAA  
 AGACTCAATCTCTTTATGCG  
 TTCTGGTACATCTGTTTCATC

**A/Panama NA mRNA**

ATGTTACAGTAGTTACCAGG  
 GTTGCATTATGCTTGA  
 CTATTATTGTTGGTTCACAC  
 TATGGTGGTGTGTCAGAT  
 CAGCGGAAAGCCGAATTGAA  
 TCAGGATCGATGACACATA  
 AATGCCTGTTGTTAGTGT  
 CATTATCAATAGGGTTCGA  
 CCCAAATGAAATGGAACACC  
 TGCTATACACACTTGCTTGG  
 ATCGTGACAACCTGAGCTGG  
 CGTAAATGAAGCTAGCAGTT  
 ATACTATCTACAAGTCTCCC  
 CTGAGGATTTTTTGGACCA  
 CAAACGCATTCCGACTCCTG  
 TACTGTACAAGTTCCATTGA  
 TGAGCACTTCTGACAATTT  
 ATAACAGGAGCACTCCTCGA  
 ATCTGACACCAGGATATCGA  
 TTATATCTACGATGGGCCTA  
 AACAAGTCTGAGCACACAT  
 AATGGCTACTGCTGGAGCTG  
 CTTCTTCAATTGTTAGGATCC  
 TTTGGAGTTAGGTTTGGACC  
 TGACTTGCCTATTTATCTGC  
 CGGACATATTACCTTTTCA  
 ACTCCACATAAAAGCACCGA  
 AATACTGTTTGGAGTCCACC  
 CTGAGGTGCCACAAAACACA  
 CATGAGCCTGTTCCATATGT

**A/Panama PA mRNA**

GATCATCAAGTTCTACCACT  
 TACTACTGTCCATGCCATTG  
 TCCAGTAGTGTTCAGATAC  
 GTCACCTCCAATTTGATGAA  
 TAGCCTGGTCTTAATCCTAG  
 GTTCGAATCCATCCACATAG  
 AAGGAGGTCCATTCGGAAGT  
 AGGAATTTGGACCGCTGATA  
 GATCGCATCATATAGTGGGA  
 CTTGGAATCTTCTCCTCATT  
 AGAGCCCACTTTAGTTGACT  
 TGCAGTTGTCAAAGTCTACT  
 TGCTTCAAATCGCTTATGTC  
 TTCAGGTTCTGCTACTATCAT  
 GCTCTATCCAGATTGAATCA  
 GACACCTCTGCTGTGAAATA  
 GTACTCAGTGGCTTACAAT  
 GTTGAAAATCGTCCATTGCT  
 AAATTTGTTTTTTCGCTTCC  
 CTTCTTTTATGATGAATCC  
 CCTATCTCAAGGACACAGTA  
 CATAGGCCTTGAATTTGGC  
 CGTTTTGCTCCTCACATACAAG  
 TCTCTATCTGCTGGAGTGAC  
 GAGGACTCGGCTTCAATCAT  
 ACAGGCTATTGAACACCGAC  
 CCTTCTAATTGTGGAGATGC  
 TTTTCTTACTCCGCTGAAA  
 GAGCCTGAACAACAAGGAGC  
 AAGATCAAAGGTCCAGGTT

**A/Panama M mRNA**

AAGTCTCTGCGCGATTTCCG  
 TTTTCCCAGCAAAGACATCT  
 ATGAGAGCCTCAAGATCTGT  
 CCTTAGTCAAGGTTGACAGG  
 GCGTGAACACAACCCCAAA  
 CTCCCTCTTAAGTTTTCTAT  
 AAATGCCACTTCGGTGGTTA  
 TCACATGTTGCACATACCAG  
 CACCATTTGCCTATGAGACC  
 TAATGGATTGGTTGTTGCCA  
 AGCTGTAGTGTGGCCAAAA  
 CTGACTAGCAATCTCCATGG  
 TAGGATGAGTCCCAACGGTT  
 TCATCTCTTAGACCAGTACT  
 CATTCTGTTCTGATAGTCT

**A/Panama HA mRNA**

GTGATTGTTTTCACTAGCGT  
 CGCATATTCTACCTGTTGAG  
 TCAAGGATTTGGTGAGGACT  
 TCCTTATTTTGAAGCCATC  
 GCGTTCAACAAAAAGGTCCC  
 AACAGTTGCTGTAGGCTTTG  
 TAATCCGGCACATCATAAGG  
 ATGAGGCAACTAGTGACCTA  
 TTGTTAACTCCAGTGTGCC  
 AGAGCTTGTTCATTCTGAG  
 TTTTATTGTTCCGGCAGTGC  
 TGATTTGGTCACTGTCCGTA  
 CCTGATGCTTGAGCATATAT  
 TCGGGATTACAGTTTGTGG  
 CCGGTTTTACTATTGTCCAA  
 TAACCCCGAGGAGCAATTGA  
 GCATCTGACCTCATTATTGA  
 TGTTGCCAATTTAGAGTGT  
 TCTCTGGTACATTCCGCATC  
 CCGAATATGCCTCTAGTTTG  
 CATTCTCTATGAAACCCGCG  
 CTGAAACCGTACCAACCGTC  
 TGTGCCCTCAGAATTTTGTAT  
 ATTTGGTTGATTGCTGCTTG  
 GGAATTTCTCGTTCGTTTTT  
 ATTTCTCGAGGTCTGAAAT  
 GATCTATTTTGTGCTCTCA  
 TCAGCATTTTCCCTCAGTTG  
 AGTTCCATTTCTGATTGACC  
 TCAGTCAACACCTTTGATC

**A/Panama NS mRNA**

TCTTGGTCTACAACCTTGCTT  
 GAAGCCGATCAAGGAATGGG  
 CTTAGGGACCTCTGATCTCG  
 TGATGTCTAGACCGAGAGTG  
 CTTCTTCCAGAACTTTTCT  
 GTCATTTTAAAGTGCCTCATC  
 TATCGCGAAGCAGGTGTGGA  
 CCTCAATAGTCTGTCAGTT  
 ATGAACCAATTTCTTGACAA  
 CACTTTTTGCTTGGGCAATTA  
 ATACTATGGTCTCTAGTCGG  
 TCTTCCGGTGAAGCCCTTAG  
 GTGAGATTTCCGCAACAACCT

**A/Mallard PB2 vRNA**

GTGTTGATAGGGCAAGGAGA  
 TGCGAAAGGGGAGAAGGCTA  
 GAGTGGAAATCTGCGGTATTA  
 AAGATGCAGGTGCTTTGACA  
 CAACCAAGAGGGCTCACAGTC  
 GGGGTTCCAGGAATGAGGATA  
 TCTTCTCTGACTGTGAACGT  
 CACCGGAACAGAGTAGGATG  
 ATAAAGCTCTACCATTTCG  
 AGGCCAGTATAGTGGATTTG  
 AAGATGGAGTTTGAGCCCTT  
 CTGTGAAGATTCAGTGGTCC  
 AAATGGTCCGGAATCAGTGC  
 CATCGTCTATGATGTGGGAG  
 GGGAACAGAGAAGCTGACGA  
 CAGAGGGGAACCGTGCCTTT  
 ACTGAGAGAGTGGTCTGAG  
 GAGGAGTGAGAGTCAGTAAA  
 GATCGGAATATTGCCTGACA  
 GACAAGCAGCGTGATATCG  
 GAGCATCAACGAATTGAGCA  
 GATGTGTTGGGGACATTTGA  
 AGACCCCTACAATGTTATACA  
 CCCAGTACAGAGATGTCACT  
 AGACGAGCAGTCAATCGCTG  
 GTGTTGCATTTGACTCAAGG  
 CGGGACTCTAGCATACTTAC  
 CCCTGTGTTCAACTATAACA  
 AGAACGCTATTCCAGCAGAT  
 CTCCTGAAGAGGTTAGTGAA

**A/Mallard NP vRNA**

GGATGATGGAAAGTGCCAGA  
 GCAGAACATCTGACATGAGG  
 GCATTTACAGGGAACACTGA  
 CGAAAGGGCGACCATTATGG  
 CAGTACAGAGAAATCTTCCC  
 AGAGCATCTGCAGGACAAT  
 TGGAGGAAACACCAACCAGC  
 ATTGGGCTATAAGAACCAGG  
 AACTATCCACCAGAGGAGTC  
 GACAAGAGTGGTCCCAAGAG  
 GAGTATCAAGTTTCATCAGA  
 CATTCTGCAGCGTTTGAAGA  
 GAGCCAATTGGTATGGATGG  
 AAAACAGCCAGGTCTTCAGT  
 ATAGATCCTTTTCGTTCTCT  
 AGAAGGATACTCTGTTGTCG  
 GCCAGTGGATATGACTTTGA  
 GAGGATCAGTGGCCATAAG  
 AATCCTGGGAATGCTGAAAT  
 GGATCAAGTACGAGAAAGCA  
 TCGGATGATAAAGCGAGGGA  
 CGGGACGATGGTATGGAAC  
 CTCTGATGCAAGGATCAACC  
 ACTGGTATGGACCCAAGAAT  
 CAACCTGAATGATGCCACAT  
 GTCTCACTCATCTGATGATC  
 GCGAACACCGGAGAAGACGC  
 GAGATCAGGAAGATCTGGCG  
 GGATGAGGGAGTTGATTCTG  
 ATCTACCGAAGGAGAGACGG

**A/Mallard PB1 vRNA**

ACAGAAGGCCAGTTGGAATT  
 TACAGATGCCACAGAGGTGA  
 GCTCTTCAGCTATTCATCAA  
 CTGGGATTAACGAATCGGCT  
 GGATTTGTAGCCAACCTCAG  
 TGGTTGGGATCAATATGAGC  
 ATGAGAATCAGAATCCTCGG  
 CCGTTGGAGGGAATGAGAAA  
 ATTAGCGAGGAGCATCTGTG  
 AAGTTGAAGAGGCGGGCAAT  
 CATTGAATAGGAACCAGCCG  
 GGATAAACTGACCCAAGGTC  
 ACCATTGCCTGAGGATAACG  
 AGCATGGAGTATGATGCTGT  
 GTTCAAAGGCAGGACTGTTG  
 AAGAAGCTGTGGGACGACAC  
 AACGATCTTGACCAGCAAC  
 CCCCATAATGTTCTCAAAC  
 ACCAACCTGAATGGTTTAGA  
 ACTGGAGACAACACCAAGTG  
 GGTTCTGTACTTTGTGCGAA  
 GAGCACTGACACTGAACACA  
 TCTTCAGATCGAACGGTCTA  
 TGCTTTGGCCAACACTATAG  
 CCGAGCGGATATGCACAAAC  
 ACAACACCGAGACTGGAGC  
 CTCAGAGAAAGGGAAGTGGA  
 CAGCCATGGAACAGGAACAG  
 ACTACATTCCCTTATACTGG  
 AAAGTGCCAGCGCAAAATGC

**A/Mallard NA vRNA**

GTATCGTCGTATTTTGTGGA  
 TAAGAGGAAGGCCACAGGAG  
 CCATGGCTAATTCCAATCA  
 TTCAGGGTCAATTAGTGGTTG  
 GCCTTTGACTATGGAGATGA  
 TGATAGCTCTAGCAACAGCA  
 GTATGGCAGACTATAGCATT  
 ATCCAGACGTTAGATGTGTT  
 TTGTTTCATGTCAGCCCTTG  
 ACTATTCAATAGAGGGGA  
 CTCAGAACTCAGGAATCAGA  
 TATGATGGGATGCTTGTGA  
 ACGAATTAGCGTTCATTT  
 TCCTCATCGAACTCTTTTGA  
 CACTCGAATGGCACAATACA  
 AGGGAACCACGCTGGATAAC  
 GCCCCGATAAATGTTATCAA  
 GTTTGTCCAAAATGGTAGA  
 TGCCATGTGAACCAATCATA  
 AAAATGAGTGCAATACCCCC  
 TTGCAACAGTATGTTTCTC  
 TAGAGTATGGTGGACCTCAA  
 GGGATCCTAATAATGAGAGA  
 GAATGTTCTGTTATCCTCG  
 TGTCAGATTACAGGGTTTGC  
 CAGGAATTGGTCAAAACCGC  
 TTGTTGGTGACACACCAAGA  
 AGGAAGTGCCACAGCATATAG  
 GTATTGGTTTCATGTTCAA  
 GATGGAAAGGCATGGCTACA

**A/Mallard PA vRNA**

GGGGTTTTTCAGCTGAATCAA  
 CCCTTCAACAAATTGAGAGC  
 AAATGAGGCGATGCCTTCTT  
 CTCTACGGACTGCAATAGG  
 GTGTTCTCGAGATAGGAGAC  
 CGGAAGACTAATCTGTATGG  
 GGAGTGTACATAAACACAGC  
 TTGCAGGGCTACTGAATACA  
 ATTTTACAGCGGAAGTATCC  
 GCACATTCGAGTATGAGAA  
 GGAAGACATTGCTCCAATT  
 AGTTGGATTGAGCTTGATGA  
 GGCATGTGAATTGACAGATT  
 CTGGATCCAGAGTGAATTCA  
 CAGAGTCTAGATCGCTAGCA  
 AGACAGTATGACAGTGATGA  
 GGACTGCAAAAGATGTTAGCG  
 AGGGCATAAAACCCCAATTAC  
 GAAGACATTTTTTCGGCTGGA  
 GTATACCGCTATATGATGCA  
 TGCTCTCAACGGTTCGAAGTT  
 CTCTCAAGCTACCTGATGGG  
 CACTTTCTGAAGACAACACC  
 AGAAGTGAACGCCGAATTG  
 TGAGGGCAAGCTTTCTCAA  
 GTGGATGGATTGCAACCGAA  
 GCCTTGA AAACTTTAGAGCC  
 AAAGTCTCCACCGAACTTC  
 AAATCACAGGAACCATGCGC  
 CGAGAGAGGCCGAAGAGACAA

**A/Mallard M vRNA**

TGTCAACATAGAGCTGGAGT  
 TGGATGTTGACGATGGTCAT  
 TATCGGCAGGAACAGCAGAG  
 GCCTGAGTCTATGAGGGAAG  
 AAAGAGGGCCTTCTACGGAA  
 CGTCGCCTTAAATACGGTTT  
 TTGTGGATTCTTGATCGTCT  
 AGTATCATTGGGATCTTGCA  
 GGATGGGAGTGCAAATGCAG  
 TGAAAATTTGCAAGCCCTACC  
 TGCCGGTCTGAAAGATGATC  
 CAATTGGAACCTACCCTAGC  
 CAGATGGTGCAGGCGATGAG  
 CATGGAGTTGCTAGTCAGG  
 TACCACCAACCCACTAATTA  
 GATTGCTGATTACAGCATC  
 GAACGGTGACCACAGAAGTG  
 AGAAGTGGCTTTTGGCCTAG  
 AACAGGATGGGAACGGTGAC  
 ACAGGGCAGTCAAACCTGTAC  
 TTGGAAATGGAGACCCAAACA  
 TTAGGATTTGTGTTACGCT  
 CTGTCACTCTGACTAAGGG  
 CTCATGGAATGGCTAAAGAC  
 GAAGAACCAGCTCTCGAGG  
 GACTTGAAGATGTCTTTGCA  
 GAGGTCGAAACGTACGTTCT

**A/Mallard HA vRNA**

CGTCTATTACGAATTCCAG  
 TAGGAACGGGACTTATGACC  
 GTCTTATAATGCGGAACTCC  
 GGAGGATTCAGAACCTTGAG  
 TATGTGAAGCAGAACCCT  
 GATCACATACGGAGCATGTC  
 CACCTATTGACACCTGTATT  
 GGACGTAAGTGTATCAATA  
 GCAGACTATAATCCCTAACA  
 ATGTTTCAAGGCTCAGGAAGA  
 TATACATCTGGGGAGTTCAC  
 GTTTCACTTGGGCAGGAGTG  
 ACATTGGAGTTCATCACTGA  
 TACCAGACTATGCATCCCTT  
 GACCATTACAGATGATCAGA  
 CAGTGCCGAATGGGACAATA  
 CCTTTTAGGGACGCAATA  
 GACCATTATCGCTTTAAGCT  
 AGAATTCGCCCTTAAGTTGG  
 CTGAAGACATGGGCAATGGT  
 AGACCAGAAGGCAACTGAGG  
 AAGGAATTCCTCGAGGTAGA  
 ACCTTAAAGCACTCAGGCA  
 ACAGTCTCTACCAGGAGAAG  
 CCAGTGTGAAACGTGACTAT  
 AGGTGACTAATGCTACCGAG  
 TTTTGCTGGGGTTCATTATG  
 ATATGCAACAATCCTCACAG  
 GGAGCAAAAGCAGGGGATAT

**A/Mallard NS vRNA**

AGAACTTTCTCGTTTCAGCT  
 CTATTGCTTGAAGTAGAGCA  
 TACGTTTATGCAAGCCTTAC  
 ACAGAGAACAGCTTCGAACA  
 ATGGCTGATTGAAGAGGTGC  
 TGGCGAGAACAATTGAGTCA  
 CCTCAAAGCAGAAACGGAA  
 GTAATGAGGATGGGAGACCT  
 TACAGAGATTCGCTTGGCA  
 AACACAGTTCGAGCTCTGA  
 AAAATGCAATTGGGGTCTC  
 TCCAGGACATACTGATGAGG  
 AAATCTCACCGTTACCTTCT  
 GAAGAAGGAGCAATTGTGGG  
 CCCTAATACTACTTAGAGCT  
 TCAGTGTGATTTTTGACCCG  
 CTTTGCATCAGAATGGACCA  
 GTCAAAAATGCAATTGGGGT  
 ATCAGAATGGACCAGGCAAT  
 ATGTCAAGGGACTGGTTCAT  
 GCTACCTAAGTACACTGACT  
 AATGACTATTGCTTCAGTGC  
 GGAAGAATCTGATGAGGCAC  
 GCAAAATAGTGGAGCGGATTC  
 GACATCGAGACAGCTACTCG  
 AAGGGTAGCACTCTTGGTC  
 CGTGATCAGAAGTCCCTAAG  
 ATTCCAACACTGTGTCAAGC

275

276

277



**A/Mallard PB2 mRNA**

AGGTTTTGTAGACCTTTGGA  
 GTTTTAATCTTTGCACCTTT  
 AAGTGAACGGGACCGAAGGT  
 CGGCGTATTTTAAACCTGATT  
 AGCACTGAGATCTGAATGGC  
 TGATGACATCTTGTGCTTCT  
 TCGTTTGGGAAAACGACCTC  
 CTCTGATGTCAATATCCTGG  
 CCACCATCAAAGGAGCAATC  
 AGTCTCTCTCCAACATGTA  
 TGGTAGAATCTGGTTTTGC  
 CTCGATATACACGCTGCTTG  
 TCCCTTGAGTCAAATGCAAC  
 GTGTGTACATTTGTTCCAG  
 ACATCATATTTCTCACCTC  
 ATTTCTGGCAGCAATAATCA  
 TGATACTGTTGCTCTCCTAA  
 TCTCCAAAAGCGAAGCCAAC  
 CGCCAATTTGTACTATGG  
 AAGGATGTCCACCATCCTTA  
 TGCTCTTCTGTTGGGTTTTG  
 TGCTTTGCATATATCCACAG  
 TGAACGTGATTTAGACCCA  
 AGTGAACCTCCAAAGCTGA  
 TTTCAATGTTGGAGGTTGC  
 TATTAGTTGGATCAGCCTTC  
 CGATTGACTGCTCGTCTCTC  
 AACCAATGCCACTATGATCG  
 TTATCATGCAATCCTCTTGT  
 TTCAAATCACCTCGTACTCG

**A/Mallard NP mRNA**

TTCTTCCAACAGATGCTCTG  
 AACCTTCCAATCCACCAAC  
 TTCAGTGACATCTGTATGT  
 CTTTCATAGTCGCTGAGTTTG  
 TTATGCTGTTCTGGATCAGC  
 TGGGATGTTCTCCAGATAT  
 TAGATTGGACCTCCAGTTTT  
 ATCAGATGAGTGAGACCAGC  
 ATCATTAGGTTGGAATGCC  
 CTCTCGTCTCTGGTATGTG  
 CATTCTGGGCTCCATACAG  
 TTGATCCTTGCATCAGAGAG  
 AATTAGTTCCATCACCATCG  
 AAGTCCGTACACACAAGCAG  
 AAGTCATATCCACTGGCCAC  
 CAGAGAGTATCCTTCTCTCT  
 GACGAAAAGGATCTATTCCG  
 GAAGACCTGGCTGTTTTGAA  
 GGATTCTCATTTGGTCTAAT  
 TGATACTCTCAGGTCTTCAA  
 GATAGTTGTCCTCTTGGGAC  
 GCTTCTCAATTCGAGAGTAC  
 TGGTTCTTATAGCCCAATAT  
 CCTTTTCGAAGGGAAGATTT  
 TGAAATGCCGCCATAATGG  
 CACTTTCCATCATCCTTATG  
 AGGACTTATGGCCACTGAT  
 TCAGTAGCATTCTGGCGTTC  
 TTTCTCGTACTTGATCCATC  
 ATTTGACATTCCAGGATT

**A/Mallard PB1 mRNA**

TGTCCATGGCTGTATGGAG  
 GATGTGTTCTATTGACTGTG  
 CACTTCCCTTTCTCTGAGTA  
 TCCAGTCTCGGTGTTTGTG  
 CAATTGGATTGAGTTGGGGT  
 CTCGTTATCCTCAGGCAATG  
 AATCTGTTGTGCATATCCG  
 ACTTCCATTGTTTCAAGACA  
 TCAGTTATCCACTCTTGT  
 TTCAATGTCCAGTCATAGGT  
 TCTATAGTGTGGCCAAAGC  
 GTTAGACCCTGATCTGAA  
 TATTAGTCTCCCTGATTCT  
 CTTACTCTTCTTTGCTTG  
 CCATTTTCTTGGTCATGTTG  
 TTCTCCCTATTGTTCTTTG  
 CATTGTGTTGAGTGTGATG  
 CATTCCGGGTGTTGCAATTG  
 AGTACACGAACCCTCTGATT  
 CTCTCGCTAATGTTTCGAC  
 ACTGCTCAAGTTTCTCACAG  
 TTTTCTCATTCCCTCCAAC  
 CAGCAGATTGGCAGTTAG  
 GTGAGTTAGTCATCATCTTT  
 GTAAGGAGAGCTCTGTGTC  
 CTTGGTGTGTCTCCAGTAA  
 ATCCGAGGATTCTGATTCTC  
 TATATGTTATCATTGCCAGA  
 CATTGAGTTGGTTCTTGT  
 CGGATACTCAGGACATTTCT

**A/Mallard NA mRNA**

GGGGTATTGCACTCATTTTG  
 ATGGCACCACTTGATTGTTT  
 TCTGACATTGCGGTTTTGAC  
 GCTGCATGACACATAAGGTT  
 TTTGTTATCCAGCTGGTTT  
 CTGGACCATGCTATGCACAC  
 TAGCAGTCGCATTTCTATCA  
 TCTGATTCTGAGTTCTGAG  
 AGTTCCATTGATGCAAACGC  
 CTTTCCCTCTCTAATGAAT  
 CTGACAATGGGCTGACATGA  
 CAATGCTATAGTCTGCCATA  
 GATAGTTCTTCCATCCAAA  
 CATAACCTGAGCGTGAATCC  
 CCTCTTATCAACTCCACATA  
 CATACTAGTCTCCTGTGG  
 TAGGATGGCAACCTGCATGA  
 TCTTTTCTATTATGATTGGT  
 TTCAAATACACTATCTCCGT  
 ACTTCTTTTCTATGGTAGT  
 TTCTGTATTCTACCATTTT  
 TCCATCGGTCAATTAATCTG  
 TATTTTAGTATCAGCCCTTC  
 TCAACAAGCATCCCATATA  
 TATTTTGAGACCATGAACCA  
 CCTGAGCACACATAACTAGA  
 CCACTAATGACCCTGAAAAGT  
 GACGATACTATTTGAGGTCC  
 GGAACATTCCTCTATATGCT  
 ACGTCTGGATATCGAGGATA

**A/Mallard PA mRNA**

GTTCTGTTTCGATTTTCGGAT  
 TAAGTGTGTGCATATCGCGG  
 CCGAATACATGAAACAGACC  
 CCCCCTCATCAATAAAGTG  
 TCGGTGTTTCAATAATGCAT  
 TCTCTCCCTTCAATTATTTT  
 GTTGACGATACTATTCACCA  
 AATTTAGCTTATCGACTCC  
 CGGTTCTCTTTGTAGTCATA  
 GTGTCACCTCAATTTCAATG  
 TAGTATATGTGAACTTCCCT  
 TTTCTCTCCAGTGAATGAA  
 TTCATCAAGAGTGTAGTCCG  
 TTTTGATTCTTGCCTACTC  
 TTTCTGCTTATAGTGAAC  
 CTCTCGGACTGACGAAAGGA  
 TTCTCAATTGCTCTTTCGC  
 CATGGTTCTGTGATTTCAA  
 AAGTTCGGTGGGAGACTTTG  
 TCTAAAGTTTTCAAGGCTGG  
 GTTGAATCCATCCACATAG  
 GAGAAAGCTTGGCCTCAATG  
 CGTTTCACTTCTTTTGACAT  
 GTTGTCTTCAGAAATGGCTC  
 CATCAGGTAGCTTGAGAGGG  
 GGAACCTCGACCGTTGAGAG  
 AATTTAAGGGCATCCATCAG  
 CATGACTCGGGTCTTCGATG  
 TGATTGCATCATATAGCGGT  
 CCAGCCGAAAAATGTCTTCA

**A/Mallard M mRNA**

CTGACGGGACGATAGAGAGA  
 CCCTGCAAAGACATCTTCAA  
 TGAGAGCCTCGAGATCGGTG  
 TGCTTTGCTTTAGCCATTC  
 CTTAGTCAGAGGTGACAGGA  
 AGCGTGAACACAAATCCTAA  
 ATGTTGTTGGGTCTCCATT  
 CTTCTGTACAGTTGACTG  
 CATACAACTGGCAAGTGCAC  
 CCATCTGTTGTATATGAGA  
 AAAAGCCACTTCTGTGGTCA  
 ATGTTGTTGGGTCTCCATT  
 CTTCTGTACAGTTGACTG  
 CATACAACTGGCAAGTGCAC  
 CCATCTGTTGTATATGAGA  
 AAAAGCCACTTCTGTGGTCA  
 CTGTGAATCAGCAATCTGCT  
 TCTAATAGTGGGTTGGTGG  
 CTGACTAGCAACCTCCATGG  
 AATTGTTCTCATCGCCTGCA  
 CACTGGAGCTAGGGTGAGTT  
 AGAAGATCATCTTTCAGACC

**A/Mallard HA mRNA**

TGAAC TAGCTCGGTAGCATT  
 GCATATTTTCCCTGTTGAAG  
 CTTCCATCAAGAATCCTGTG  
 GTAGGGCATCTATTAGTGTG  
 AGACATCGCAATGAGGATCC  
 CAAAGAGATCCCATGTCTCA  
 CTGAAAGCATTGCTTCGCTC  
 GGTACATCGTAAGGATAGCA  
 GGTACGAAAGGATGCATAGT  
 CAATGTGCCTGATGATGCAA  
 CCAAGTGAACCTTCAAGTGA  
 TGAAGAAACCGTAGCAGGT  
 TCACGTTCAACTGGGTAT  
 CCCAGATGTATAAATTTGTCA  
 TTTGTGCTCGGGTGGTGAAC  
 TCCTGAGGCTGAACATACA  
 TCCTGGTAGAGACTGTGACT  
 GGGATTATAGTCTGCTGGCT  
 CCAGGGTCTAGATCCAATGT  
 ATGCTTATTCTGCCAGACTG  
 CAGGTTTACTATTGTCCAG  
 CTATTGATCACCAGTACGTC  
 AGGAGCATTAGGTTTCCAT  
 CAGTGCCCATCTTGAAGTAG  
 GACCTCATTATCGAGCTTTT  
 ACAGGTGTCAATAGGTGCAT  
 TTGGGGTGATGCATTAGAA  
 CTTGTCAATGGGATGCTTC  
 GTGATCTTGTACATTTTGG  
 CATATTTGGGACATGCTCCG  
 AACCTCAGGGTGTCTGCTT  
 TACATTCCGACTTCTGTTG  
 AATAGCCTCTGGTTTGTCT  
 CTATAAGCCTGCTATTGCA  
 ATCTATCATTCTTCCATC  
 GATGCCTGAAGCCATACCAA  
 TGCTCTGTACCTTCCGAATT  
 AGTGCTTTTAAAGGTCTGCTG  
 TTGATCTGGTCAATGGCTGC  
 AATCACTCTGTTCAATTTCC  
 GGAACCTTCTCATTCTGCTTT  
 CTGGAGAATTCCTTTTCGA  
 TTCTCAAGGTTCTGAATCCT  
 GAGTTCCGATTATAAGACC  
 TGTATGCTGATTCTCTAGGG  
 GTTCAATTTCTGAATCAGTCA  
 CCTTCTGGTCTTTTCAAACA  
 CATGTCTTCAAGATTTTCC  
 CTATGCAAGCATTGTACAC

**A/Mallard NS mRNA**

GCGAAGCCGGTCAAGGAATG  
 CTCTTAGGGACTTCTGATCA  
 CAGACCAAGAGTGTACCTC  
 CACGAGTAGTGTCTCGATG  
 AGAATCCGCTCCACTATTTG  
 TAAGTGCCTCATCAGATTCT  
 GGCAGTGAAGCAATAGTCAT  
 GTCAGTTAGGTAGCGTGAAG  
 TTGACATTTCTCAAGAGTC  
 GGCATGAGCATGAACCATGTC  
 TTATCCATTATTGCTGGTCT  
 GTTTGCTTCAATATGATGT  
 GCCGGTCAAAAATCACACTG  
 GCTCTAAGTAGTATTAGGGT  
 AATTGCTCCTTCTCTGTGA  
 GGTACGGGTGAGATTTCTCC  
 CATCAGTATGCTCGGAAGA

279 **Supplementary Table 1: FISH probe sets.** DNA oligonucleotide sequences for  
280 detection of vRNA and mRNA of A/Panama and A/Mallard.

281

282 **Supplementary Table 2**

283

284 MSC Rank 2

Experiment		Predicted	
Segments	n	Segments	n
<b>23</b>	23	<b>27</b>	38
<b>35</b>	17	<b>37</b>	16
<b>37</b>	17	<b>23</b>	12
<b>27</b>	15	<b>35</b>	10

285

286 MSC Rank 3

Experiment		Predicted	
Segments	n	Segments	n
<b>237</b>	14	<b>237</b>	31
<b>127</b>	7	<b>127</b>	12
<b>257</b>	5	267	7
234	5	<b>257</b>	4

287

288 MSC Rank 4

Experiment		Predicted	
Segments	n	Segments	n
<b>1237</b>	10	2378	16
1257	5	<b>2367</b>	8
1267	5	<b>1237</b>	7
<b>2367</b>	5	2357	5

289

290 MSC Rank 5

Experiment		Predicted	
Segments	n	Segments	n
<b>12367</b>	9	<b>12367</b>	10
23467	8	24567	7
23678	7	<b>12378</b>	5
<b>12378</b>	7	12468	5

291

292 MSC Rank 6

Experiment		Predicted	
Segments	n	Segments	n
<b>123678</b>	19	<b>123467</b>	21
<b>123467</b>	13	<b>123678</b>	16
123457	10	123578	10
<b>123567</b>	10	<b>123567</b>	9

293

294 MSC Rank 7

Experiment		Predicted	
Segments	n	Segments	n
<b>1234567</b>	41	<b>1234567</b>	57
<b>1235678</b>	41	<b>1235678</b>	31
<b>1245678</b>	26	<b>1245678</b>	25
<b>1234678</b>	17	<b>1234678</b>	19

295

296 MSC Rank 8

Experiment		Predicted	
Segments	n	Segments	n
<b>12345678</b>	355	<b>12345678</b>	319

297

298

299 **Supplementary Table 2: Comparison between experimental and predicted**  
300 **abundances n of the four most abundant MSCs in each rank for Cell 18.** The four  
301 most abundant experimental and predicted MSCs in each rank are listed. MSCs that  
302 occur at a given rank in both the experimental and predicted MSCs are bold. Especially  
303 for the higher ranks 5 to 7 there is a good agreement between experiment and model.